论文部分内容阅读
目的探究骨质疏松患者骨代谢标志物与骨密度之间的关系及临床意义。方法选择2016年2月~2017年2月期间我院收治的70例骨质疏松患者作为骨质疏松组,另选同期为诊断为骨质疏松的50例健康者作为健康对照组,测定两组患者的骨钙素(OC)、甲状旁腺激素(PTH)、25-羟基维生素D[25(OH)D]、总Ⅰ型胶原氨基端前肽(P1NP)等生化指标及骨密度。结果骨质疏松组患者的骨密度低于健康对照组,差异显著(P<0.05);骨质疏松组患者的P1NP为(40.86±9.02),显著低于健康对照组的(44.88±9.67),组间差异显著(P<0.05);骨质疏松组患者的OC为(26.03±8.03),显著高于对照组的(21.05±7.82),组间差异显著(P<0.05);两组的PTH、25(OH)D等指标比较无显著差异(P>0.05)。结论骨代谢标志物OC、P1NP与骨密度具有一定的相关性,能反应出骨质疏松患者的骨代谢变化,是综合评价骨质疏松症的重要指标。
Objective To explore the relationship between bone metabolism markers and bone mineral density in patients with osteoporosis and its clinical significance. Methods Seventy osteoporosis patients admitted to our hospital from February 2016 to February 2017 were selected as the osteoporosis group and 50 healthy people diagnosed as osteoporosis at the same period were selected as the healthy control group. Two groups The biochemical indexes such as osteocalcin (OC), parathyroid hormone (PTH), 25-hydroxyvitamin D [25 (OH) D] and total type Ⅰ collagen amino-terminal propeptide (P1NP) Results The BMD in osteoporosis group was significantly lower than that in healthy control group (P <0.05). The average level of P1NP in osteoporosis group was (40.86 ± 9.02), significantly lower than that in healthy control group (44.88 ± 9.67) (P <0.05). The OC in osteoporosis group was (26.03 ± 8.03), which was significantly higher than that in control group (21.05 ± 7.82) (P <0.05). The PTH , 25 (OH) D and other indicators no significant difference (P> 0.05). Conclusions OC, P1NP, a marker of bone metabolism, have a certain correlation with bone mineral density and can reflect the changes of bone metabolism in patients with osteoporosis. It is an important index for comprehensive evaluation of osteoporosis.